According to DRG epidemiology, more than 35 million people in the United States...
According to DRG epidemiology, more than 35 million people in the United States suffer migraines, and more than 10% of migraineurs suffer from chronic migraine (CM). Migraine prophylaxis is a core,......
The triptan drug class dominates the prescription acute treatment migraine...
The triptan drug class dominates the prescription acute treatment migraine market, particularly now that the class is almost fully generic. Despite the array of approved treatment options, new ther......
Coming December 2018 Market Outlook The migraine prophylaxis...
Coming December 2018 Market Outlook The migraine prophylaxis market stands poised for disruption following the launch of three anti-CGR......
According to DRG epidemiology, more than 33 million people in the EU5 suffer...
According to DRG epidemiology, more than 33 million people in the EU5 suffer from migraines an......
According to DRG epidemiology, more than 35 million people in the United...
According to DRG epidemiology, more than 35 million people in the United States suffer migraines, and more than 10% of migraineurs suffer from c...
The migraine market stands on the verge of a renaissance; new and exciting...
The migraine market stands on the verge of a renaissance; new and exciting therapies targeting the CGRP peptide could reach the market beginni......
For migraine patients who suffer from 15 or more migraine days per month (...
For migraine patients who suffer from 15 or more migraine days per month (chronic migraine) and/or those patients who suffer from long-lasting migraine attacks or do not experience sufficient re......
Coming Soon – June 2019 Market Outlook The migraine prophyla...
Coming Soon – June 2019 Market Outlook The migraine...
Coming Soon – November 2019 Market Outlook The migraine prophylax...
Coming Soon – November 2019 Market Outlook The migraine...
Last Updated 4 December 2014 The migraine market consists of a multitude of...
Last Updated 4 December 2014 The migraine market consists of a multitude of therapies that either acutely treat migraine attacks or serve as prophylactic treatment. Among acute antim......
Migraine, estimated to affect 36 million people in the United States, is a...
Migraine, estimated to affect 36 million people in the United States, is a disabling disease characterized by unilateral or bilateral headache pain that may be accompanied by aura and the associate......
For the estimated 36 million people in the United States who experience...
For the estimated 36 million people in the United States who experience migraines, multiple prescription therapies are available that have proved effective in acutely treating migraine pain and its......
For the estimated 35 million people in the United States who experience...
For the estimated 35 million people in the United States who experience migraines, multiple prescription therapies are available that have proved effective in acutely treating migraine pain and its......
The migraine market consists of a multitude of therapies that either acutely...
The migraine market consists of a multitude of therapies that either acutely treat migraine attacks or serve as prophylactic treatment. Among acute antimigraine therapies, triptans and NSAIDs/gener......
The migraine market is comprised of an array of prescription acute and...
The migraine market is comprised of an array of prescription acute and prophylactic treatments. Today, oral triptan products—the gold standard of acute treatment—already do, or will...
Market Outlook With four anti-CGRP-targeted MAbs (e.g., Amgen/Novartis&rsqu...
Market Outlook With four anti-CGRP-targeted MAbs (e.g., Amgen/Novartis&rsqu......
Market Outlook The migraine prophylaxis market stands poised for disruption...
Market Outlook The migraine prophylaxis market stands poised for disruption with the launch of Amgen/Novartis’s Aimovig (erenumab) in May 2018 and three additional...
The triptan drug class dominates the market for approved prescription acute...
The triptan drug class dominates the market for approved prescription acute treatments for migraine. Despite the array of approved triptan options, most of them generic, new reformulations have l......
DRG Epidemiology’s coverage of migraine comprises epidemiological estimates...
DRG Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries. We report the prevalence of migraine for each country, as well as ann...
DRG Epidemiology’s coverage of migraine comprises epidemiological estimates...
DRG Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of migraine for each country, as w...
